European Medicines Agency’s data protection notice for grant procedures
Submitted by Anonymous (not verified) on 1 February 2024 - 14:55
European Medicines Agency’s data protection notice for grant procedures
Careers at European Medicines Agency (EMA) - Guidance on selection and recruitment
Submitted by Anonymous (not verified) on 1 February 2024 - 14:51
Careers at European Medicines Agency (EMA) - Guidance on selection and recruitment
Human medicines European public assessment report (EPAR): Albrioza, sodium phenylbutyrate,Ursodoxicoltaurine, Date of refusal: 05/01/2024, Status: Refused
Submitted by Anonymous (not verified) on 1 February 2024 - 12:48
Human medicines European public assessment report (EPAR): Albrioza, sodium phenylbutyrate,Ursodoxicoltaurine, Date of refusal: 05/01/2024, Status: Refused
Orphan designation: vactosertib Treatment of osteosarcoma, 25/07/2023 Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 11:11
Orphan designation: vactosertib Treatment of osteosarcoma, 25/07/2023 Positive
Orphan designation: Ulefnersen Treatment of amyotrophic lateral sclerosis Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 11:08
Orphan designation: Ulefnersen Treatment of amyotrophic lateral sclerosis Positive
Orphan designation: Humanised IgG1 monoclonal antibody against TfR1 conjugated to exon 44 specific phosphorodiamidate morpholino oligonucleotide via a non-cleavable linker Treatment of Duchenne muscular dystrophy, 13/10/2023 Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 11:06
Orphan designation: Humanised IgG1 monoclonal antibody against TfR1 conjugated to exon 44 specific phosphorodiamidate morpholino oligonucleotide via a non-cleavable linker Treatment of Duchenne muscular dystrophy, 13/10/2023 Positive
Orphan designation: 2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol Treatment of myelofibrosis, 13/10/2023 Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 10:58
Orphan designation: 2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol Treatment of myelofibrosis, 13/10/2023 Positive
Orphan designation: zedenoleucel Treatment of acute myeloid leukaemia, 25/02/2023 Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 10:56
Orphan designation: zedenoleucel Treatment of acute myeloid leukaemia, 25/02/2023 Positive
Orphan designation: Autologous adipose-derived mesenchymal stem cells Treatment of oesophageal atresia, 21/04/2023 Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 10:52
Orphan designation: Autologous adipose-derived mesenchymal stem cells Treatment of oesophageal atresia, 21/04/2023 Positive
Orphan designation: Setmelanotide Treatment of acquired hypothalamic obesity, 13/10/2023 Positive
Submitted by Anonymous (not verified) on 1 February 2024 - 10:48
Orphan designation: Setmelanotide Treatment of acquired hypothalamic obesity, 13/10/2023 Positive